Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2026)

Harmony Biosciences Holdings has disclosed EBITDA Margin across 7 years of filings, most recently posting 14.73% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 14.73%, down 1003.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.12% (down 444.0% YoY), and the FY2025 annual result was 18.3%, down 206.0% from the prior year.
• EBITDA Margin came in at 14.73% for Q1 2026 at Harmony Biosciences Holdings, up from 9.22% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 74.91% in Q3 2022 to a low of 6.67% in Q2 2024.
• The 5-year median for EBITDA Margin is 24.37% (2024), against an average of 24.75%.
• Across the five-year window, EBITDA Margin jumped 8682 bps in 2022 and plunged 5090 bps in 2023, its largest moves.
• Harmony Biosciences Holdings' EBITDA Margin stood at 37.83% in 2022, then sank by 57 bps to 16.11% in 2023, then jumped by 51 bps to 24.37% in 2024, then tumbled by 62 bps to 9.22% in 2025, then jumped by 60 bps to 14.73% in 2026.
• The last three EBITDA Margin figures came in at 14.73% (Q1 2026), 9.22% (Q4 2025), and 21.29% (Q3 2025), per Business Quant data.